Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla et al. · The Lancet · 2012 · 2K citations · Full text

Metastatic Soft-tissue Sarcoma, Placebo-controlled Phase 3, Medicine +8

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

Oncology, Pathology, Advanced Soft-tissue Sarcoma +5

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Scott M. Wilhelm, Jacques Dumas, Lila Adnane et al. · International Journal of Cancer · 2010 · 1.3K citations · Full text

Tyrosine Kinase, Pathology, Pharmacotherapy +18

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine et al. · The Lancet Oncology · 2018 · 716 citations · Full text

Oncology, Ipilimumab Treatment, Clinical Trials +8

Sample size tables for exact single‐stage phase II designs

Roger A’Hern · Statistics in Medicine · 2001 · 385 citations

Experiment Design, Design, Optimal Experimental Design +8